open access to scientific and medical research

Back to Journals » Lung Cancer: Targets and Therapy » Volume 10

Case report

Noteworthy comment: There are several problems arising from TKIs resistance mechanisms in patients with EGFR-mutant squamous cell carcinoma of the lung. This case report adds to evidence that dual therapy (Osimertinib and Crizotinib) should be useful to EGFR-mutant lung cancers with emergent MET amplification as acquired resistance. This is a very well written case, which would be of interest to many specialties, with a clear discussion and relevant references.

Highly-accessed

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification

Total article views		HTML views	PDF downloads	Totals
8,836	Dovepress*	6,798+	1,692	8,490
	PubMed Central*	2,038	467	2,505
	Totals	8,836	2,159	10,995
*Since 12 March 2019

Total mentioned	Facebook	Delicious	Reddit	Twitter	Others
4	1	0	0	1	2

View citations on PubMed Central and Google Scholar